Quantbot Technologies LP Invests $1.70 Million in Omada Health, Inc. $OMDA

Quantbot Technologies LP purchased a new stake in Omada Health, Inc. (NASDAQ:OMDA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 77,200 shares of the company’s stock, valued at approximately $1,695,000. Quantbot Technologies LP owned 0.13% of Omada Health as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Perceptive Advisors LLC purchased a new stake in Omada Health during the second quarter valued at about $44,402,000. Millennium Management LLC increased its position in shares of Omada Health by 1,195.0% in the fourth quarter. Millennium Management LLC now owns 2,272,168 shares of the company’s stock worth $35,855,000 after acquiring an additional 2,096,705 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Omada Health during the second quarter valued at approximately $48,775,000. Loomis Sayles & Co. L P raised its holdings in shares of Omada Health by 23.0% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,855,721 shares of the company’s stock valued at $29,283,000 after acquiring an additional 346,588 shares during the period. Finally, Jefferies Financial Group Inc. purchased a new stake in shares of Omada Health in the 4th quarter valued at approximately $16,948,000.

Insider Activity at Omada Health

In other news, CFO Steven L. Cook sold 33,000 shares of the stock in a transaction on Friday, June 26th. The shares were sold at an average price of $19.89, for a total transaction of $656,370.00. Following the transaction, the chief financial officer owned 133,359 shares in the company, valued at $2,652,510.51. This represents a 19.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Sean P. Duffy sold 25,886 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $22.68, for a total transaction of $587,094.48. Following the transaction, the chief executive officer owned 411,861 shares in the company, valued at $9,341,007.48. This represents a 5.91% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 254,726 shares of company stock worth $5,370,496. Insiders own 6.38% of the company’s stock.

Omada Health Price Performance

Shares of OMDA stock opened at $24.08 on Tuesday. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $26.92. The stock’s 50-day moving average is $21.75 and its two-hundred day moving average is $16.87. The firm has a market cap of $1.47 billion, a P/E ratio of 481.60 and a beta of 1.73.

Omada Health (NASDAQ:OMDA) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.10. The business had revenue of $87.83 million during the quarter, compared to analyst estimates of $80.93 million. Omada Health had a return on equity of 2.60% and a net margin of 1.39%. As a group, research analysts expect that Omada Health, Inc. will post 0.09 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on OMDA shares. JPMorgan Chase & Co. raised their price objective on shares of Omada Health from $26.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, August 14th. Citizens Jmp boosted their target price on shares of Omada Health from $27.00 to $32.00 and gave the company a “market outperform” rating in a research note on Friday, August 14th. Robert W. Baird increased their target price on Omada Health from $15.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, August 12th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $24.00 target price on shares of Omada Health in a research report on Friday, August 7th. Finally, Citigroup reiterated an “outperform” rating on shares of Omada Health in a report on Friday, August 14th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $26.50.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.